JP2004529881A - 合成ワクチン剤 - Google Patents

合成ワクチン剤 Download PDF

Info

Publication number
JP2004529881A
JP2004529881A JP2002565614A JP2002565614A JP2004529881A JP 2004529881 A JP2004529881 A JP 2004529881A JP 2002565614 A JP2002565614 A JP 2002565614A JP 2002565614 A JP2002565614 A JP 2002565614A JP 2004529881 A JP2004529881 A JP 2004529881A
Authority
JP
Japan
Prior art keywords
immunogen
poly
epitope
polyhydroxy polymer
antigenic determinant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002565614A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004529881A5 (cg-RX-API-DMAC10.html
Inventor
ニールセン,クラウス,グレゴリウス
コーフォード,ペーター
Original Assignee
ファーメクサ エイ/エス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/DK2001/000113 external-priority patent/WO2001062284A2/en
Priority claimed from US09/785,215 external-priority patent/US7135181B2/en
Application filed by ファーメクサ エイ/エス filed Critical ファーメクサ エイ/エス
Publication of JP2004529881A publication Critical patent/JP2004529881A/ja
Publication of JP2004529881A5 publication Critical patent/JP2004529881A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2002565614A 2001-02-19 2002-02-19 合成ワクチン剤 Pending JP2004529881A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/DK2001/000113 WO2001062284A2 (en) 2000-02-21 2001-02-19 Novel method for down-regulation of amyloid
US09/785,215 US7135181B2 (en) 2000-02-21 2001-02-20 Method for down-regulation of amyloid
DKPA200101231 2001-08-20
US33754301P 2001-10-22 2001-10-22
PCT/DK2002/000112 WO2002066056A2 (en) 2001-02-19 2002-02-19 Synthetic vaccines comprising polyhydroxypolymer carriers

Publications (2)

Publication Number Publication Date
JP2004529881A true JP2004529881A (ja) 2004-09-30
JP2004529881A5 JP2004529881A5 (cg-RX-API-DMAC10.html) 2005-12-22

Family

ID=35160895

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002565614A Pending JP2004529881A (ja) 2001-02-19 2002-02-19 合成ワクチン剤

Country Status (10)

Country Link
EP (1) EP1363664A2 (cg-RX-API-DMAC10.html)
JP (1) JP2004529881A (cg-RX-API-DMAC10.html)
CN (1) CN100562338C (cg-RX-API-DMAC10.html)
AU (1) AU2002233166B2 (cg-RX-API-DMAC10.html)
CA (1) CA2440197A1 (cg-RX-API-DMAC10.html)
IL (1) IL157475A0 (cg-RX-API-DMAC10.html)
NO (1) NO335602B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ527720A (cg-RX-API-DMAC10.html)
WO (1) WO2002066056A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA200400895B (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004024183A1 (en) * 2002-09-12 2004-03-25 Pharmexa A/S Immunization against autologous ghrelin
WO2005037190A2 (en) * 2003-09-03 2005-04-28 Dendritherapeutics, Inc. Multiplex vaccines
WO2005046605A2 (en) * 2003-11-07 2005-05-26 University Of Rochester Compositions and methods of treating neurological diseases
AU2012229234B2 (en) * 2011-03-11 2016-02-25 Flow Pharma Inc. Vaccine formulation of mannose coated peptide particles
CN103665113A (zh) * 2012-09-14 2014-03-26 深圳市安群生物工程有限公司 人Aβ42抗原决定簇多肽、抗原、抗体、用途及试剂盒
RU2635517C1 (ru) * 2016-09-14 2017-11-13 Закрытое акционерное общество "Институт фармацевтических технологий" (ЗАО "ИФТ") Синтетический иммуноген для защиты и лечения от зависимости от психоактивных веществ
CN112165956A (zh) * 2018-04-10 2021-01-01 Ac免疫有限公司 抗Aβ治疗性疫苗
MA52180A (fr) 2018-04-10 2021-02-17 Ac Immune Sa Vaccins thérapeutiques anti-abêta

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0625910B1 (en) * 1992-02-11 2003-07-23 Henry M. Jackson Foundation For The Advancement Of Military Medicine Dual carrier immunogenic construct
AU4377793A (en) * 1992-05-20 1993-12-13 Johns Hopkins University, The Alternative receptor therapy
KR100731820B1 (ko) * 1998-10-05 2007-06-25 파멕사 에이/에스 치료적 백신화를 위한 새로운 방법

Also Published As

Publication number Publication date
ZA200400895B (en) 2005-05-03
CN100562338C (zh) 2009-11-25
AU2002233166B2 (en) 2006-06-29
CA2440197A1 (en) 2002-08-29
NZ527720A (en) 2005-03-24
WO2002066056A2 (en) 2002-08-29
CN1893970A (zh) 2007-01-10
IL157475A0 (en) 2004-03-28
NO335602B1 (no) 2015-01-12
NO20040431L (no) 2004-04-16
WO2002066056A8 (en) 2004-04-29
EP1363664A2 (en) 2003-11-26
WO2002066056A3 (en) 2003-01-03

Similar Documents

Publication Publication Date Title
US7097837B2 (en) Synthetic vaccine agents
JP4776131B2 (ja) ヘテロクリティックアナログおよび関連方法
RS51699B (sr) Beta-amiloid-analog-t-ćelijski-epitop vakcina
KR20210104745A (ko) 합성 펩티드 면역원에 대한 면역 자극제로서 인공 무차별적 t 헬퍼 세포 에피토프
JP2633881B2 (ja) 免疫調節組成物及びそれらの使用
JP2002520000A (ja) 免疫応答を刺激するための発現ベクターおよびそのベクターの使用方法
JP2011231111A (ja) 複合ワクチン
US20040191264A1 (en) Synthetic vaccine agents
US20050049197A1 (en) Induction of immune response against desired determinants
WO2002034287A2 (en) Therapeutic vaccine formulations containing chitosan
AU2020204779B2 (en) Vaccines targeting neoepitopes
US20020172673A1 (en) Method for down-regulating IgE
AU2002233166B2 (en) Synthetic vaccines comprising polyhydroxypolymer carriers
US20050063952A1 (en) Immunogenic CEA
US20040037840A1 (en) Novel therapeutic vaccine formulations
Dakappagari et al. Intracellular delivery of a novel multiepitope peptide vaccine by an amphipathic peptide carrier enhances cytotoxic T‐cell responses in HLA‐A* 201 mice
AU2002233166A1 (en) Synthetic vaccines comprising polyhydroxypolymer carriers
EP0427768A1 (en) Polypeptide pertussis toxin vaccine
AU2003285280A1 (en) Targeting single epitopes
US20020160012A1 (en) Vaccine chip technology exploiting immunostimulating fragment of TGF-BETA
AU2006228872A1 (en) Immunogenic EGFR peptides comprising foreign Tcell stimulating epitope
US20030190322A1 (en) Immunostimulating properties of a fragment of tgf-beta
RU2845190C2 (ru) Вирусоподобные частицы cmv, модифицированные путем слияния
RU2839585C2 (ru) Искусственные неизбирательные эпитопы клеток т-хелперов как иммунные стимуляторы для синтетических пептидных иммуногенов
Yang et al. Peptide Vaccines

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050128

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050128

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080507

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20081014